Daily Brief Health Care: BioStem Technologies , BenQ BM Holding Cayman Corp., Ensysce Biosciences , Oryzon Genomics and more

• BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
• The company announced its 4Q and full year 2024 results.
• The company continues to execute at a high level by posting record revenue and earnings that beat expectations.

• The expansion space of BenQ is severely limited as the market has been saturated in Jiangsu Province. Due to DRG, future revenue/net profit growth would continue to be under pressure. 
• Low profit margin of general hospitals is a common problem in this industry due to pain points of business model.It’s difficult to achieve improvement.Investors need to be aware of this.
• BenQ’s valuation should be lower than Hygeia due to weaker profitability, smaller revenue scale, lower growth outlook.Post-money valuation before IPO of US$375 million (or about RMB2.7 billion) is already expensive

• Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world.
• Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid.
• The company announced that data from its study of its overdose protection drug showed the compound to be effective and safe-furthering the case for FDA approval of this much-needed treatment.

Oryzon Genomics has announced that the first patient has been dosed in iadademstat’s Phase I/II trial, sponsored by the National Cancer Institute, (NCI) in extensive-stage small cell lung cancer (SCLC). The trial is evaluating lead oncology candidate iadademstat in combination with an immune checkpoint inhibitor (ICI), either atezolizumab or durvalumab, with primary objectives focussed on safety, tolerability, dose-finding and efficacy. Should the results of this trial be positive, they may support Oryzon’s plans for its STELLAR programme, a randomised, multi-centre Phase II study of iadademstat in combination with a checkpoint inhibitor for first-line extensive-stage SCLC. Management has indicated that additional data from STELLAR could aid an accelerated approval pathway.